United Therapeutics Corp

CEO Martine Rothblatt’s 10b5‑1 option sales signal a planned, long‑term exit at United Therapeutics, reflecting confidence in the company’s growth prospects.

Insider moves at United Therapeutics (UTX) reveal a balanced CFO confidence strategy—buying below market and selling options to manage risk amid biotech volatility.

United Therapeutics’ insider trades reveal a mixed‑signal narrative: CEO Martine Rothblatt’s modest buying amid heavy 10‑b‑5 sales signals confidence but also highlights liquidity pressures that could influence stock volatility.

United Therapeutics CEO Martine Rothblatt’s 10B5‑1 purchase of 9,500 shares signals confidence in the company’s Tyvaso pipeline and strong rally, offering investors insight into insider sentiment amid a 90% year‑to‑date gain.

US insider trades reveal CFO’s deep‑discount purchase of UTX shares, a bullish confidence signal for investors amid a strong biotech pipeline.

Rothblatt’s 10‑b‑5‑1 plan shows UTHR shares bought at $146, while options sell‑offs hit $532‑$545—insider confidence, strategic liquidity, and future upside.

Insider buy of 9,500 UTHR shares by CEO Martine Rothblatt signals long‑term confidence in United Therapeutics’ pulmonary hypertension growth, balancing profit and position.

United Therapeutics CEO’s 10b5‑1 buy‑sell plan signals bullish confidence and long‑term commitment to the company’s pulmonary hypertension pipeline.

Insider buys signal confidence in United Therapeutics: CEO and EVP purchase shares under 10‑b‑5‑1 plan, suggesting a bullish outlook and potential upside as the company pursues its pipeline.

United Therapeutics CEO’s 10b5‑1 option exercise shows disciplined selling—little impact on stock, but worth tracking for investors.